Discontinue Wellbutrin and Switch to a First-Line ADHD Stimulant or SSRI
Given the patient's worsening anxiety after two weeks on bupropion 150 mg XL, you should discontinue the medication and switch to either a first-line stimulant for ADHD (methylphenidate or amphetamine) combined with an SSRI for the GAD and depression, or use an SSRI alone if the depression/anxiety are the primary concerns. Bupropion is explicitly a second-line agent for ADHD at best 1, and while it can treat comorbid anxiety in some patients with depression, the FDA label clearly warns that anxiety is a known side effect that may represent a precursor to worsening depression 2.
Why This Approach
Bupropion's Limited Role in This Clinical Context
For ADHD: Bupropion has "no data to support" its use as a single agent to treat both ADHD and depression 1. The guidelines are explicit that bupropion and tricyclics are "second-line agents, at best, for treating ADHD" 1.
For Anxiety: The FDA label lists anxiety, agitation, and panic attacks as reportable adverse events that should prompt consideration of discontinuation 2. While recent research suggests bupropion may have comparable anxiolytic effects to SSRIs in patients with mild-to-moderate anxiety symptoms of depression 3, 4, 5, your patient is experiencing increased anxiety—a clear treatment-emergent adverse effect.
The stimulating properties of bupropion (norepinephrine-dopamine reuptake inhibition) can provoke anxiety, particularly at therapeutic doses 3. A 2025 systematic review notes that while bupropion generally improves anxiety in depression, SSRIs show a "modest advantage" in patients with high baseline anxiety 4.
The Correct Treatment Algorithm for ADHD + GAD + Depression
Step 1: Prioritize the ADHD with a stimulant trial
The 2002 AACAP guidelines provide clear direction for comorbid ADHD and anxiety 1:
- "The clinician should proceed with a stimulant trial" even when anxiety is present 1
- Stimulants have rapid onset, allowing quick assessment of ADHD symptom response
- "Reduction in morbidity caused by the ADHD symptoms can have a substantial impact on the depressive symptoms" 1
- Contrary to older beliefs, recent trials show ADHD patients with comorbid anxiety do NOT have less robust responses to stimulants 1
Specific stimulant options:
- Methylphenidate: 5-20 mg three times daily 1
- Dextroamphetamine: 5 mg three times daily to 20 mg twice daily 1
Step 2: Reassess anxiety and depression after stimulant trial
- If ADHD symptoms improve but anxiety/depression remain problematic, add an SSRI to the stimulant 1
- If both ADHD and mood/anxiety symptoms remit with stimulant alone, no additional changes needed 1
Alternative approach if stimulants are contraindicated or refused:
Start an SSRI as monotherapy, which treats both the GAD and depression effectively. The SSRI can address the anxiety and depressive symptoms, and you can reassess ADHD symptom burden once mood is stabilized.
Critical Pitfalls to Avoid
Don't Continue Bupropion Hoping Anxiety Will Resolve
The FDA label explicitly states: "Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms" 2.
Your patient's increased anxiety after two weeks represents a treatment-emergent adverse effect. While some patients tolerate bupropion well for anxiety 5, 6, this patient clearly does not.
Don't Add an SSRI to Bupropion at This Point
While combination therapy can be appropriate in some contexts, your patient hasn't demonstrated any benefit from bupropion yet and is experiencing worsening symptoms. Adding another medication creates unnecessary polypharmacy and makes it impossible to determine which agent is helping or harming.
Don't Assume Bupropion Will Eventually Work for ADHD
The evidence is clear that bupropion is inferior to stimulants for ADHD 7. A 2024 guideline notes: "it is important to consider that bupropion is not as efficacious as stimulants for the treatment of ADHD" 7. Bupropion is only suggested as an alternative "particularly for individuals requiring treatment for co-occurring depression" in contexts where stimulants cannot be used (e.g., pregnancy) 7.
Monitoring After Medication Change
If you start a stimulant:
- Monitor for anxiety worsening (though evidence suggests this is uncommon) 1
- Assess ADHD symptom response within 1-2 weeks
- Monitor blood pressure and heart rate
- Reassess mood and anxiety symptoms after ADHD symptoms stabilize
If you add or switch to an SSRI:
- Monitor for initial activation/anxiety (typically transient)
- Assess response over 4-6 weeks
- Watch for suicidality, especially in young adults 2
When combining stimulant + SSRI:
- No significant drug interactions expected
- Monitor for cumulative side effects (insomnia, appetite suppression)
- This combination is explicitly supported by guidelines for refractory anxiety in ADHD patients 1
Evidence Nuances
The research on bupropion and anxiety shows mixed signals. A 2008 meta-analysis of 2,890 patients found no difference in anxiolytic efficacy between bupropion and SSRIs when treating anxiety symptoms in major depression 5. A small 2008 pilot trial (n=24) suggested bupropion XL had comparable efficacy to escitalopram for generalized anxiety disorder 6. However, these studies examined patients who tolerated bupropion—they don't address what to do when a patient develops increased anxiety on bupropion, which is your clinical scenario.
Recent 2025 reviews acknowledge that bupropion's "stimulating properties can also provoke anxiety, particularly at higher doses" 3, and that "SSRIs may be preferable for severe depression with anxious distress" 3. The systematic review notes SSRIs showed advantage "in highly anxious subgroups" 4.
Your patient with GAD (generalized anxiety disorder) likely represents a "highly anxious" presentation, making SSRIs the more appropriate choice for the mood/anxiety component of their illness.